Benjamin Izar

18.3k total citations · 1 hit paper
64 papers, 1.5k citations indexed

About

Benjamin Izar is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Benjamin Izar has authored 64 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 28 papers in Molecular Biology and 20 papers in Immunology. Recurrent topics in Benjamin Izar's work include Cancer Immunotherapy and Biomarkers (23 papers), Cancer Genomics and Diagnostics (13 papers) and CAR-T cell therapy research (13 papers). Benjamin Izar is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), Cancer Genomics and Diagnostics (13 papers) and CAR-T cell therapy research (13 papers). Benjamin Izar collaborates with scholars based in United States, Germany and United Kingdom. Benjamin Izar's co-authors include Peter K. Sorger, Jia‐Ren Lin, Parin Shah, Sandro Santagata, Shu Wang, Shaolin Mei, Clarence Yapp, Levi A. Garraway, Asaf Rotem and Torsten Hain and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Benjamin Izar

55 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes

2018 376 citations Jia‐Ren Lin, Benjamin Izar et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Benjamin Izar United States	20	806	582	328	296	248	64	1.5k
Rachael E. Hawtin United States	18	1.3k 1.6×	645 1.1×	320 1.0×	167 0.6×	237 1.0×	53	2.0k
Daniel Schulz Germany	17	1.5k 1.8×	554 1.0×	662 2.0×	301 1.0×	245 1.0×	36	2.4k
Wolfgang Haensch Germany	25	803 1.0×	682 1.2×	454 1.4×	294 1.0×	158 0.6×	33	2.1k
Bhavneet Bhinder United States	20	891 1.1×	333 0.6×	199 0.6×	156 0.5×	415 1.7×	51	1.7k
Min Ni United States	19	1.0k 1.3×	253 0.4×	284 0.9×	147 0.5×	261 1.1×	33	2.3k
Lars Rønn Olsen Denmark	22	676 0.8×	282 0.5×	397 1.2×	98 0.3×	167 0.7×	51	1.3k
Yvonne Reid United States	16	895 1.1×	262 0.5×	128 0.4×	92 0.3×	242 1.0×	25	1.5k
Pier Federico Gherardini Italy	22	1.3k 1.6×	804 1.4×	927 2.8×	98 0.3×	154 0.6×	48	2.4k
Svetlana Sadekova United States	16	1.5k 1.9×	1.1k 1.9×	1.1k 3.4×	205 0.7×	648 2.6×	23	3.1k

Countries citing papers authored by Benjamin Izar

Since Specialization

Citations

This map shows the geographic impact of Benjamin Izar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Izar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Izar more than expected).

Fields of papers citing papers by Benjamin Izar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Izar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Izar. The network helps show where Benjamin Izar may publish in the future.

Co-authorship network of co-authors of Benjamin Izar

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Izar. A scholar is included among the top collaborators of Benjamin Izar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Izar. Benjamin Izar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Caprio, Lindsay, Luke L. Cai, Shivem B. Shah, et al.. (2025). micronuclAI enables automated quantification of micronuclei for assessment of chromosomal instability. Communications Biology. 8(1). 361–361. 1 indexed citations

Wehrenberg-Klee, Eric, Antoine Desîlets, Marlana Orloff, et al.. (2025). Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients. The Oncologist. 30(10).

Friedman, Claire F., Juanita Lopez, Mark R. Middleton, et al.. (2024). 750P Phase I safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC). Annals of Oncology. 35. S569–S570. 1 indexed citations

Nguyen, Trang, Qiuqiang Gao, Zhe Zhu, et al.. (2024). Suppressing PD-L1 Expression via AURKA Kinase Inhibition Enhances Natural Killer Cell-Mediated Cytotoxicity against Glioblastoma. Cells. 13(13). 1155–1155.

Henick, Brian S., Peter D. Koch, Justin F. Gainor, et al.. (2024). Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. Journal for ImmunoTherapy of Cancer. 12(12). e009301–e009301. 4 indexed citations

Shah, Parin, Neeharika Kothapalli, Shivem B. Shah, et al.. (2024). Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens. Nature Biotechnology. 43(3). 384–395. 18 indexed citations

Manji, Gulam A., Michael May, Ilenia Pellicciotta, et al.. (2024). Abstract PR05: CheMo4METPANC: Combination Chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in METastatic treatment-naïve PANCreatic adenocarcinoma. Cancer Research. 84(2_Supplement). PR05–PR05.

Manji, Gulam A., Michael May, Ilenia Pellicciotta, et al.. (2024). CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-naïve pancreatic adenocarcinoma.. Journal of Clinical Oncology. 42(16_suppl). TPS4208–TPS4208.

Izar, Benjamin, J. Fried, Kevin J. Clerkin, et al.. (2024). Recurrent melanoma 25 years after initial diagnosis, presenting as metastatic disease early after heart transplantation. Cardio-Oncology. 10(1). 71–71.

10.

Hamid, Omid, Juanita Lopez, Daniel G. Olson, et al.. (2024). Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM).. Journal of Clinical Oncology. 42(16_suppl). 9507–9507. 10 indexed citations

11.

Caprio, Lindsay, Christy Hong, Amit Dipak Amin, et al.. (2024). Abstract 5360: Relief of chromosomal instability-induced cGAS-STING signaling sensitizes STK11-mutant non-small cell lung cancer to immune checkpoint blockade. Cancer Research. 84(6_Supplement). 5360–5360.

12.

Su, Jiayu, Xi Fu, Guojie Zhong, et al.. (2023). Smoother: a unified and modular framework for incorporating structural dependency in spatial omics data. Genome biology. 24(1). 291–291. 3 indexed citations

13.

Ager, Casey R., Mingxuan Zhang, Matthew G. Chaimowitz, et al.. (2023). KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response. Journal for ImmunoTherapy of Cancer. 11(9). e006782–e006782. 7 indexed citations

14.

Cartwright, Adam N.R., Shengbao Suo, S Badrinath, et al.. (2021). Immunosuppressive Myeloid Cells Induce Nitric Oxide–Dependent DNA Damage and p53 Pathway Activation in CD8+ T Cells. Cancer Immunology Research. 9(4). 470–485. 34 indexed citations

15.

Krummel, Daniel A. Pomeranz, Tahseen H. Nasti, Benjamin Izar, et al.. (2020). Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases. International Journal of Radiation Oncology*Biology*Physics. 108(1). 157–163. 30 indexed citations

16.

Rapisuwon, Suthee, Benjamin Izar, Cory Batenchuk, et al.. (2019). Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 7(1). 61–61. 36 indexed citations

17.

Du, Ziming, Jia‐Ren Lin, Rumana Rashid, et al.. (2019). Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. Nature Protocols. 14(10). 2900–2930. 72 indexed citations

18.

Melms, Johannes C., Rohit Thummalapalli, Huihui Ye, et al.. (2018). Alpha-fetoprotein (AFP) as tumor marker in a patient with urothelial cancer with exceptional response to anti-PD-1 therapy and an escape lesion mimic. Journal for ImmunoTherapy of Cancer. 6(1). 89–89. 10 indexed citations

19.

Izar, Benjamin, Meredith M. Regan, & David F. McDermott. (2017). Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era. The Cancer Journal. 23(1). 63–67. 8 indexed citations

20.

Izar, Benjamin, Julia Rotow, Justin F. Gainor, Jeffrey W. Clark, & Bruce A. Chabner. (2013). Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. Pharmacological Reviews. 65(4). 1351–1395. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact